News
A federal judge has rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's ...
A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its drug shortage list, ending the sale of compounded versions of the ...
A trial pitting weight loss jab Mounjaro against competitor Wegovy ended with one clear winner, and Mounjaro is getting ...
5h
Zacks Investment Research on MSNCan Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space?Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...
WITH Mounjaro users shedding nearly double the amount of weight compared to its other counterparts, it’s no wonder the ...
GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...
Weight loss drugs, including Wegovy (semaglutide) and Mounjaro (tirzepatide), are becoming increasingly popular among those ...
A Swiss-led team has developed an AI-driven legged robot that can play badminton against human opponents, demonstrating precise coordination and accuracy. Alice Rizzo reports.
While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...
“GLP-1 drugs don’t just curb appetite – they dull the desire to drink at a metabolic level. With cravings suppressed and ...
Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...
Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results